Importantly, however, anti‐CSF‐1 therapy also seemed to improve the access of the standard‐of‐care chemotherapy temozolomide to gliomas, with a significant increase in median survival when compared to chemotherapy alone. The gene discussed is CSF1; the disease is glioma.